According to a study published on April 30, 2026, in Hepatobiliary & Pancreatic Diseases International, a combined bio-histological framework known as the Seven-Up score can substantially reduce overtreatment of early T cell-mediated rejection (TCMR) after liver transplantation. Conducted at Université catholique de Louvain in Brussels, Belgium, under the leadership of Prof. Jan P. Lerut, the research evaluated 421 consecutive adult liver transplant recipients with complete follow-up through December 2024 to address the persistent clinical challenge of intensive immunosuppression complications.
The Clinical Burden of Post-Transplant Overtreatment
Long-term outcomes after liver transplantation remain hampered by complications linked to intensive immunosuppression. According to the study, infections, cardiovascular events, kidney dysfunction, and metabolic disorders affect 10% to 40% of recipients. For decades, the fear of graft loss has driven high-dose immunosuppression protocols. Yet clinical experience has long hinted that some rejection episodes may resolve spontaneously. The Banff histology system—the current gold standard—relies on biopsy findings alone to guide treatment. However, studies have shown that clinical suspicion correlates poorly with biopsy results, and interobserver variability is high.
Did you know? Under a traditional biopsy-only strategy, all 157 patients (37.3%) in the cohort with Banff scores of 6-9 would have received steroid treatment. When the Seven-Up score was applied, only 19 patients (4.5%) qualified for treatment during the first 15 days, sparing 138 patients from early steroid boluses.
How the Seven-Up Score Integrates Biology and Histology
The Seven-Up score integrates two distinct components to refine patient management. According to the research paper (DOI: 10.1016/j.hbpd.2026.04.008), the histological component uses the Banff score ranging from 0 to 9 from a protocol biopsy performed on post-operative day 7. The biological component—termed the Bio-score, which ranges from 0 to 4—captures dynamic changes in three routine blood markers between day 5 and day 7. These indicators comprise an upward shift in total bilirubin, an increase in eosinophil counts (incorporating absolute eosinophils ≥600/μL as a supplementary criterion), alongside a reduction in platelet levels. Requiring both a Banff score of 6 or higher and a Bio-score greater than 2 defines clinically relevant rejection that warrants immediate intervention.
| Strategy Type | Patients Meeting Criteria | Percentage Treated | Patients Spared Steroids |
|---|---|---|---|
| Traditional Biopsy-Only | 157 patients (Banff 6-9) | 37.3% | 0 |
| Seven-Up Score Approach | 19 patients (Banff ≥6 & Bio-score >2) | 4.5% | 138 patients (32.8%) |
Patient Outcomes and Diagnostic Accuracy
Long-term graft and patient survival were comparable between treated and untreated groups, according to the published data. Furthermore, the Bio-score demonstrated good diagnostic accuracy for very early clinically relevant TCMR, yielding an area under the curve of 0.78 with a 95% confidence interval of 0.68 to 0.89.
“The key message is simple: not every rejection seen under the microscope needs to be treated,” the authors said. “For decades, we’ve been treating the biopsy rather than the patient. Our data show that the liver allograft is remarkably resilient—most early histological rejection resolves without intervention. The Seven-Up score gives clinicians a practical, objective way to distinguish the rare cases that truly need therapy from the many that can be safely observed. In an era when we’re increasingly aware of the long-term harms of over-immunosuppression, this is a step toward more personalized, safer care.”
Future Implications for Transplant Protocols
The Seven-Up score offers an immediately implementable framework for early post-transplant decision-making. For centers utilizing immunosuppression-minimization strategies, the score helps avoid unnecessary steroid pulses, thereby reducing the risk of infections, diabetes, and other steroid-related complications without compromising graft survival. Additionally, the biological component may serve as a non-invasive surrogate for liver biopsy. This is particularly relevant in partial liver transplantation—such as split and living donor procedures—where early biopsies carry higher procedural risks. Beyond clinical practice, the authors note that the score provides a more meaningful endpoint for future immunosuppression trials by moving beyond histological rejection to capture clinically relevant rejection that actually requires treatment.
Frequently Asked Questions
What is the Seven-Up score?
The Seven-Up score is a combined bio-histological assessment tool that integrates a post-operative day 7 Banff histology score with a dynamic Bio-score derived from routine blood markers between days 5 and 7 to identify clinically relevant T cell-mediated rejection after liver transplantation.
How many patients were included in the Université catholique de Louvain study?
The study evaluated 421 consecutive adult liver transplant recipients with complete follow-up through December 2024.
What blood markers are evaluated in the Bio-score?
The Bio-score evaluates escalating levels of total bilirubin, rising eosinophil counts (with absolute eosinophils ≥600/μL serving as an extra criterion), and a diminishing platelet count.
Where was the research published?
The findings were published on April 30, 2026, in the journal Hepatobiliary & Pancreatic Diseases International under DOI: 10.1016/j.hbpd.2026.04.008.
To stay informed on the latest developments in transplant medicine, subscribe to our professional newsletter or explore our related clinical research archives.
Keep reading